High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.
Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).
Axitinib treatment may result in higher drug costs compared with everolimus.
Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.
A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.
Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).
Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).
A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.
Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.
In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).